All

Results: 67969-67980 of 73113

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression

Top Five 2024 Cybersecurity Predictions by KnowBe4 Cybersecurity Experts

Divergent Technologies, Inc. Announces Closing of Upsized $230 Million Series D Capital Raise

PR Newswire associated0

Study confirms powerful effects of Lumenato® on improving skin structure and enhancing beauty from within

Esri’s ArcGIS Basemaps and ArcGIS Living Atlas Data to Be Integrated into Autodesk Software Environment

Spryker Partners with Vertex to Integrate Tax and Compliance Solutions for Global Customers

Q4 Inc. Reports Continued Progress in Third Quarter 2023 Results

Q4 Inc. Enters into Definitive Agreement to be Acquired by Sumeru Equity Partners

BrightHR Explores AI’s Impact on the Legal Sector

PR Newswire associated0

Phabuilder Set to Launch Marine-Degradable Straws and Cutlery

Achim Degen appointed to Chief Executive Officer of Colliers in Germany

PR Newswire associated0

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)